Thrombotic Microangiopathy Associated With Synthetic Cannabinoid Receptor agonists

Authors

Michael Karass, New York Medical College
Savneek Chugh, New York Medical CollegeFollow
Gabriela Andries
A Mamorska-Dyga
John C. Nelson, New York Medical CollegeFollow
Praveen Chander, New York Medical CollegeFollow

Journal Title

Stem Cell Investigation

First Page

43

Document Type

Article

Publication Date

5-1-2017

Department

Medicine

Abstract

Marijuana is one of the most commonly used recreational drugs in the United States. As marijuana is illegal in the majority of countries, the use of readily available and unregulated synthetic cannabinoids (SCBs) has increased. Little is known about the potential adverse effects of SCBs especially in regards to their nephrotoxicity. Case reports of acute kidney injury (AKI) from acute tubular injury secondary to their use have been reported. However, the exact pathology, mechanism, and extent of renal injury remain unknown. We report the first case of biopsy proven thrombotic microangiopathy (TMA) associated with SCBs resulting in AKI. The patient suffered significant morbidity with loss of renal function eventually requiring renal replacement therapy.

Recommended Citation

Karass, M., Chugh, S., Andries, G., Mamorska-Dyga, A., Nelson, J. C., & Chander, P. (2017). Thrombotic Microangiopathy Associated With Synthetic Cannabinoid Receptor agonists. Stem Cell Investigation, 4, 43. https://doi.org/10.21037/sci.2017.05.05

Publisher's Statement

Originally published in Stem Cell Investigation; 4:43. The original material can be found here.